Acromegaly Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. The detailed market research, industry sector growth and development, and new product introductions covered in this report on the Acromegaly Market are of great assistance to the important new commercial players joining the market.

 

This Acromegaly Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Acromegaly Market report analysis.

 

Regions Covered in the Report-

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Click the link to get a Sample Copy of the Report before purchase: https://www.delveinsight.com/sample-request/acromegaly-market

 

Acromegaly: An Overview

Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or noncancerous tumors on the pituitary. These benign tumors are called Adenomas.

 

Key highlights of the Acromegaly Market Report

• As per the DelveInsight’s estimate, the total number of prevalent cases of acromegaly in 2017 were found to be 61,022 in the 7MM.
• As per DelveInsight’s analysis, 57,971 acromegaly cases originated from pituitary adenomas and 3,051 from benign tumors at other sites in 2017.
• According to DelveInsight’s analysis, majority of the cases of Acromegaly is originated with adenomas at Pituitary gland and rest are because of benign tumor at other sites.

 

Acromegaly Epidemiology Insights

Acromegaly is a very rare disorder caused, in most cases, by a tumor of the pituitary gland that produces too much growth hormone (GH). Nearly all pituitary tumors, including those that cause acromegaly, are benign, and not malignant. However, they can become quite large and expand beyond the normal confines of the pituitary gland.

 

Acromegaly Epidemiology Segmentation in the 7MM

• Total Prevalent Population
• Origin-based Prevalent Population
• Diagnosed Cases
• Treatable Cases
• Diagnosed Cases Based on Type

 

Acromegaly Treatment Market

The current treatment method for Acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the diseases causing areas, and on reducing GH and IGF-1 levels to normal. Although, the primary treatment method for Acromegaly is transsphenoidal surgery, although all the patients are not eligible for surgery. Patients diagnosed with microadenomas and those with macroadenomas not close to other key structures in the brain, such as the nerves supplying the eyes or nearby blood vessels, are recommended for surgery. The cure rate of surgery is about 80% for microadenomas and 40‒50% for macroadenomas.

 

Acromegaly Market Insights

As per the literature reviews by Lim et al., titled “The role of combination medical therapy in the treatment of acromegaly,” pegvisomant and SSA combination has demonstrated good biochemical control in the majority of patients, and may allow individual drug dosage reductions, but patients require close monitoring for liver enzyme elevations. The combination of cabergoline, to SSA is relatively well tolerated and most likely to be effective in patients with very mild IGF-1 elevations. It was also found that the combination of pegvisomant and cabergoline may be useful in a select group of patients with mild IGF-1 elevations, particularly in the setting of intolerance to SSA or when the cost of SSA-Peg therapy is prohibitive.

 

Acromegaly Emerging Therapies

The emerging therapies for the treatment of Acromegaly includes Octreotide capsules (Chiasma Pharma), Veldoreotide (Strongbridge Biopharma), CAM2029 (Camurus), CRN00808 (Crinetics Pharmaceuticals), IONIS-GHR-LRx (Ionis Pharmaceuticals), ATL1103 (Antisense Therapeutics), and MTD201 (Midatech). Octreotide capsules have been granted orphan designation in the US and the European Union for the potential treatment of Acromegaly.

 

Make an Enquiry Before Buying- https://www.delveinsight.com/sample-request/acromegaly-market

 

Table of Content

1. Key Insights

2. Executive Summary

3. Competitive Intelligence Analysis for Acromegaly

4. Acromegaly Market Overview at a Glance

5. Acromegaly Disease Background and Overview

6. Patient Journey

7. Acromegaly Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Acromegaly Unmet Needs

10. Key Endpoints of Acromegaly Treatment

11. Acromegaly Marketed Products

12. Acromegaly Emerging Therapies

13. Acromegaly Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Acromegaly Market Outlook

16. Access and Reimbursement Overview of Acromegaly

17. KOL Views

18. Acromegaly Market Drivers

19. Acromegaly Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Acromegaly Market Report Highlights

• In the coming years, the Acromegaly (MMA) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly (MMA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for Acromegaly (MMA). The launch of emerging therapies will significantly impact the Acromegaly (MMA) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acromegaly (MMA)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Why should you buy this report?

• The report will help in developing business strategies by understanding trends shaping and driving the Acromegaly (MMA) market
• To understand the future market competition in the Acromegaly (MMA) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Acromegaly (MMA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Acromegaly (MMA) market
• To understand the future market competition in the Acromegaly (MMA) market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/